Great Point Partners’s BridgeBio Pharma BBIO Stock Holding History

Great Point Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,050,000	Closed	-$10.4M	–	43
2022 Q3	$10.4M	Buy	+1,050,000	New	+$10.9M	2.51%	16
2020 Q1	–	Sell	-78,400	Closed	-$2.75M	–	40
2019 Q4	$2.75M	Buy	+78,400	New	+$2.17M	0.24%	33

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Great Point Partners's BBIO Position: Q4 2022 in Review

Great Point Partners sold out of BridgeBio Pharma (BBIO) in Q4 2022, closing a stake of 1,050,000 shares — an estimated $10.4M sold.

Great Point Partners first reported a position in BBIO in Q4 2019 and held it in 2 quarters. The position peaked at $10.4M in Q3 2022. 179 funds tracked by Wall St. Rank hold BBIO as of Q4 2022.

Great Point Partners reported no remaining BridgeBio Pharma position as of Q4 2022 after selling out during the quarter.
Great Point Partners sold 1,050,000 BridgeBio Pharma shares in Q4 2022, an estimated $10.4M.
Great Point Partners first reported a position in BridgeBio Pharma in Q4 2019 and held it in 2 quarters.
Great Point Partners's BridgeBio Pharma position peaked at $10.4M in Q3 2022.
179 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2022.

Based on Great Point Partners's 13F filing for Q4 2022, filed 14 Feb 2023.